<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-147457</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment</dc:title>
<dc:description xml:lang="en">Mastocytosis is a term used to describe a heterogeneous group of disorders characterized by clonal proliferation of mast cells in different organs. The organ most often affected is the skin. The World Health Organization classifies cutaneous mastocytosis into mastocytoma, maculopapular cutaneous mastocytosis, and diffuse mastocytosis. The systemic variants in this classification are as follows: indolent systemic mastocytosis (SM), aggressive SM, SM with an associated clonal hematological non-mast cell lineage disease, mast cell leukemia, mast cell sarcoma, and extracutaneous mastocytoma. The two latest systemic variants are rare. Although the course of disease is unpredictable in children, lesions generally resolve by early adulthood. In adults, however, the disease tends to persist. The goal of treatment should be to control clinical manifestations caused by the release of mast cell mediators and, in more aggressive forms of the disease, to reduce mast cell burd (AU)</dc:description>
<dc:creator>Torrelo, A</dc:creator>
<dc:creator>Matito, A</dc:creator>
<dc:creator>Azaña, JM</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las mastocitosis constituyen un grupo heterogéneo de enfermedades caracterizadas por la proliferación clonal de mastocitos en distintos órganos, siendo la localización cutánea la más frecuente. La Organización Mundial de la Salud (OMS) clasifica las mastocitosis cutáneas en mastocitomas, mastocitosis máculo-papulosas y mastocitosis cutánea difusa, mientras que las formas sistémicas incluyen las mastocitosis indolentes, las agresivas, las asociadas a otra hematopatía monoclonal y la leucemia mastocitaria; el sarcoma mastocitario y el mastocitoma extracutáneo son variantes muy poco frecuentes. Aunque la evolución de la enfermedad en los niños es impredecible, con frecuencia las lesiones desaparecen durante la infancia; en los adultos la enfermedad tiende a persistir. El tratamiento se dirige a controlar las manifestaciones clínicas debidas a la acción de los mediadores mastocitarios, mientras que las formas agresivas requerirán de tratamientos dirigidos a reducir la masa mastocitaria (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;107(1): 15-22, ene.-feb. 2016. ilus, tab</dc:source>
<dc:identifier>ibc-147457</dc:identifier>
<dc:title xml:lang="es">Actualización en mastocitosis. Parte 2: categorías, pronóstico y tratamiento</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d11812</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d52246^s22073</dc:subject>
<dc:subject>^d6792^s22073</dc:subject>
<dc:subject>^d6793^s22073</dc:subject>
<dc:subject>^d6794^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d37263^s22067</dc:subject>
<dc:subject>^d287</dc:subject>
<dc:subject>^d37261^s22032</dc:subject>
<dc:subject>^d12137^s22066</dc:subject>
<dc:subject>^d19240^s22011</dc:subject>
<dc:subject>^d37261^s22012</dc:subject>
<dc:subject>^d37261^s22067</dc:subject>
<dc:subject>^d19240^s22067</dc:subject>
<dc:subject>^d37262^s22067</dc:subject>
<dc:subject>^d22715^s22012</dc:subject>
<dc:subject>^d22715^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>201602</dc:date>
</metadata>
</record>
</ibecs-document>
